Royal Bank of Canada’s Hepion Pharmaceuticals HEPA Stock Holding History

Royal Bank of Canada’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-290	Closed	-$15K	–	7083
2024 Q2	$15K	Buy	+290	New	+$21.4K	﹤0.01%	6182
2024 Q1	–	Hold	0	–	–	–	7239
2023 Q4	–	Sell	-2	Closed	-$378	–	7311
2023 Q3	$0	Hold	2	–	–	﹤0.01%	7280
2023 Q2	$1K	Buy	+2	New	+$1.23K	﹤0.01%	7008
2022 Q4	–	Hold	0	–	–	–	7421
2022 Q3	–	Hold	0	–	–	–	7606
2021 Q1	–	Hold	0	–	–	–	7530
2020 Q4	–	Hold	0	–	–	–	7152
2019 Q2	–	Hold	0	–	–	–	6982
2019 Q1	–	Hold	0	–	–	–	6923
2018 Q4	–	Hold	0	–	–	–	6898
2018 Q3	–	Hold	0	–	–	–	6805
2018 Q2	–	Hold	0	–	–	–	6627
2018 Q1	–	Hold	0	–	–	–	6519
2017 Q4	–	Hold	0	–	–	–	6677
2017 Q3	–	Hold	0	–	–	–	6803
2017 Q2	–	Hold	0	–	–	–	6640
2017 Q1	–	Hold	0	–	–	–	6425
2016 Q4	–	Hold	0	–	–	–	6554
2016 Q3	–	Hold	0	–	–	–	6279
2016 Q2	–	Hold	0	–	–	–	6241
2016 Q1	–	Hold	0	–	–	–	6210
2015 Q4	–	Hold	0	–	–	–	6218
2015 Q3	–	Hold	0	–	–	–	6483
2015 Q2	–	Hold	0	–	–	–	6319
2015 Q1	–	Hold	0	–	–	–	5904

Other funds holding HEPA

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada's HEPA Position: Q3 2024 in Review

Royal Bank of Canada sold out of Hepion Pharmaceuticals (HEPA) in Q3 2024, closing a stake of 290 shares — an estimated $15K sold.

Royal Bank of Canada first reported a position in HEPA in Q2 2023 and held it in 3 quarters. The position peaked at $15K in Q2 2024. 16 funds tracked by Wall St. Rank hold HEPA as of Q3 2024.

Royal Bank of Canada reported no remaining Hepion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Royal Bank of Canada sold 290 Hepion Pharmaceuticals shares in Q3 2024, an estimated $15K.
Royal Bank of Canada first reported a position in Hepion Pharmaceuticals in Q2 2023 and held it in 3 quarters.
Royal Bank of Canada's Hepion Pharmaceuticals position peaked at $15K in Q2 2024.
16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.